- Preface
- Contributors
- Symbols and Abbreviations
- Classes of recommendations and levels of evidence
- Amendments and Updates
- Chapter 1.1 Hypertension
- Chapter 1.2 Dyslipidaemia
- Chapter 1.3 Metabolic syndrome and diabetes
- Chapter 1.4 Thrombosis
- Chapter 2.1 Acute coronary syndrome: STEMI and NSTEMI
- Chapter 2.2 Chronic stable angina
- Chapter 2.3 Coronary artery spasm and microvascular angina
- Chapter 2.4 Takotsubo syndrome
- Chapter 3.1 Heart failure
- Chapter 3.2 Heart transplantation
- Chapter 4.1 Atrial fibrillation
- Chapter 4.2 Supraventricular (narrow complex) tachycardias
- Chapter 4.3 Ventricular arrhythmias
- Chapter 4.4 Bradyarrhythmias
- Chapter 4.5 Syncope
- Chapter 5.1 Valvular heart disease
- Chapter 5.2 Myocarditis and pericardial syndromes
- Chapter 5.3 Cardiomyopathy
- Chapter 5.4 Pulmonary hypertension
- Chapter 6.1 Kidney disease
- Chapter 6.2 Pregnancy and lactation
- Chapter 6.3 Liver disease
- Chapter 7.1 Major drug interactions
- Chapter 8.1 Cardiovascular drugs—from A to Z
- Chapter 9.1 Non-cardiac drugs affecting the heart—from A to Z
- Index
(p. 261) Valvular heart disease
- Chapter:
- (p. 261) Valvular heart disease
- Author(s):
Francesca Mantovani
- DOI:
- 10.1093/med/9780198759935.003.0016
July 29, 2020: This chapter has been re-evaluated and remains up-to-date. No changes have been necessary.
Valvular heart disease is common, and any of the four valves of the heart can be affected, although left-sided valvular disease is far commoner than right-sided disease. Treatment depends on the valvular disease type and severity but, when severe and symptomatic, usually involves mechanical intervention. Asymptomatic patients without objective parameters suggesting high morbid or lethal risk are closely observed clinically, until surgical indications develop. Although often prescribed, no rigorous evidence supports pharmacological therapy in most chronic valve diseases, although drugs may be useful in acute valvular diseases or as a bridge to surgery in severely decompensated patients. Moreover, given the rising proportion of frail older people with symptomatic degenerative valve disease, in whom the risks of mechanical intervention are prohibitive, medical treatment could be the only option.
Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.
Please subscribe or login to access full text content.
If you have purchased a print title that contains an access token, please see the token for information about how to register your code.
For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.
- Preface
- Contributors
- Symbols and Abbreviations
- Classes of recommendations and levels of evidence
- Amendments and Updates
- Chapter 1.1 Hypertension
- Chapter 1.2 Dyslipidaemia
- Chapter 1.3 Metabolic syndrome and diabetes
- Chapter 1.4 Thrombosis
- Chapter 2.1 Acute coronary syndrome: STEMI and NSTEMI
- Chapter 2.2 Chronic stable angina
- Chapter 2.3 Coronary artery spasm and microvascular angina
- Chapter 2.4 Takotsubo syndrome
- Chapter 3.1 Heart failure
- Chapter 3.2 Heart transplantation
- Chapter 4.1 Atrial fibrillation
- Chapter 4.2 Supraventricular (narrow complex) tachycardias
- Chapter 4.3 Ventricular arrhythmias
- Chapter 4.4 Bradyarrhythmias
- Chapter 4.5 Syncope
- Chapter 5.1 Valvular heart disease
- Chapter 5.2 Myocarditis and pericardial syndromes
- Chapter 5.3 Cardiomyopathy
- Chapter 5.4 Pulmonary hypertension
- Chapter 6.1 Kidney disease
- Chapter 6.2 Pregnancy and lactation
- Chapter 6.3 Liver disease
- Chapter 7.1 Major drug interactions
- Chapter 8.1 Cardiovascular drugs—from A to Z
- Chapter 9.1 Non-cardiac drugs affecting the heart—from A to Z
- Index